Clinical Trial Update: A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating orally administered KT-621 for moderate to severe atopic dermatitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• KT-621

Snippet

Sponsor: Kymera Therapeutics, Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING